WHO ICTRP trial
Randomized phase II study of two cross-over sequences comprising outpatient…
JPRN-UMIN000003002 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000003002 |
|---|---|
| Public title | Randomized phase II study of two cross-over sequences comprising outpatient chemotherapies, vinorelbine/cyclophosphamide (R1) and temozolomide/etoposide (R2), for relapsed or refractory solid tumors in children and young adults |
| Scientific title | Randomized phase II study of two cross-over sequences comprising outpatient chemotherapies, vinorelbine/cyclophosphamide (R1) and temozolomide/etoposide (R2), for relapsed or refractory solid tumors in children and young adults - Cross-over rPII of outpatient chemotherapies for refractory pediatric… |
| Primary sponsor | Group for " Cross-over rPII of outpatient chemotherapies for refractory pediatric solid tumors " |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase II |
| Countries | Japan |
| Conditions | Relapse or refractory pediatric solid tumor |
| Interventions | VNR+CY: weekly intravenous VNR day1,8,15 with daily oral CY, to be repeated every 4 weeks TMZ+VP: 5 day schedule oral TMZ and 12 day schedule oral VP, to be repeated every 4 weeks |
| Registration date | Sep 1, 2010 |
| Target size | 45 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: